Corbus Advances Early-Stage Obesity Drug CRB-913: What Investors Should Watch Now

Corbus Pharmaceuticals Holdings (CRBP) announced an update on their ongoing clinical study.

Study Overview: Corbus Pharmaceuticals is running a Phase 1b trial titled “A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Range Finding Study of the Efficacy, Safety, and Pharmacokinetics of CRB-913 in Participants With Obesity With a Single Cohort Open-label Exploratory Pharmacokinetic Lead-In.” The study aims to test how safe CRB-913 is, how the body handles it, and whether it can help reduce weight in adults with obesity. This early-stage work is important because it will shape dose selection and the go/no-go decision for larger, more expensive trials in the weight-loss market.

Intervention/Treatment: The treatment under review is CRB-913, an oral drug taken once daily. It is designed to help people with obesity lose weight while tracking safety and how much drug enters the bloodstream. A placebo tablet, also taken once daily, is used as a control to see if CRB-913 delivers added benefit beyond lifestyle or background changes.

Study Design: The trial has two parts. Part 1 is an open-label lead-in where a small group of healthy adults receive a single dose of CRB-913 so researchers can measure drug levels and short-term safety. Part 2 is a randomized, double-blind, placebo-controlled study, where participants with obesity are assigned by chance to low, medium, or high doses of CRB-913, or to placebo, in parallel groups. Neither patients nor study doctors know who receives which treatment. The main goal is treatment-focused: find a safe, effective dose range and see early signals of weight loss.

Study Timeline: The study was first submitted on December 16, 2025, marking the formal start of the regulatory process and signaling Corbus’s move into the obesity space. The most recent update was posted on January 22, 2026, showing that the protocol and status are active and under review. The trial is currently listed as “recruiting,” meaning enrollment is underway, but primary completion and final completion dates have not yet been reported; those milestones will be key catalysts when early efficacy and safety data become available.

Market Implications: For investors, this update confirms that Corbus is executing on its obesity program, a high-profile therapeutic area dominated by leaders like Novo Nordisk and Eli Lilly. As a Phase 1b asset, CRB-913 is high risk but offers high optionality: any clear signal of meaningful weight loss with acceptable safety could re-rate Corbus’s valuation and attract partnership interest. Near term, the main impact is on sentiment rather than revenue—recruiting progress and on-time updates support confidence in management, while delays or safety flags would weigh on the stock. In a crowded obesity market, differentiation on safety, convenience, or price will be critical, so investors should watch future readouts for signs CRB-913 can carve out a niche alongside established GLP-1 drugs.

The study is ongoing and has been recently updated, with further details available on the ClinicalTrials portal under NCT07310901.

To learn more about CRBP’s potential, visit the Corbus Pharmaceuticals Holdings drug pipeline page.